Selected research
Industry Research
Personalized Therapy Biosimulation Platform Industry Research Report 2026
Market perspective
The global Personalized Therapy Biosimulation Platform market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Personalized Therapy Biosimulation Platform market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Personalized Therapy Biosimulation Platform market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Personalized Therapy Biosimulation Platform market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Personalized Therapy Biosimulation Platform include Schrodinger, In Silico Biosciences, Genedata, Physiomics, Insilico Biotechology, Chemical Computing Group ULC(CCG), Evidera, AnyLogic and Shanghai Lide, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Personalized Therapy Biosimulation Platform market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Personalized Therapy Biosimulation Platform.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Personalized Therapy Biosimulation Platform Market by Company
Schrodinger
In Silico Biosciences
Genedata
Physiomics
Insilico Biotechology
Chemical Computing Group ULC(CCG)
Evidera
AnyLogic
Shanghai Lide
Cellworks Group
Certara
Simulation Plus
Personalized Therapy Biosimulation Platform Segment by Type
Pharmacokinetic
Pharmacoeconomics
Personalized Therapy Biosimulation Platform Segment by Application
Pharmaceutical and Biotech Companies
Research Institutions
Hospital
Others
Personalized Therapy Biosimulation Platform Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Personalized Therapy Biosimulation Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Personalized Therapy Biosimulation Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Personalized Therapy Biosimulation Platform.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Personalized Therapy Biosimulation Platform companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pharmacokinetic
- Pharmacoeconomics
Applications
- Pharmaceutical and Biotech Companies
- Research Institutions
- Hospital
- Others
Companies covered
- Schrodinger
- In Silico Biosciences
- Genedata
- Physiomics
- Insilico Biotechology
- Chemical Computing Group ULC(CCG)
- Evidera
- AnyLogic
- Shanghai Lide
- Cellworks Group
- Certara
- Simulation Plus
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Personalized Therapy Biosimulation Platform by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Pharmacokinetic
- 2.2.3 Pharmacoeconomics
- 2.3 Personalized Therapy Biosimulation Platform by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical and Biotech Companies
- 2.3.3 Research Institutions
- 2.3.4 Hospital
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Personalized Therapy Biosimulation Platform Breakdown Data by Type
- 3.1 Global Personalized Therapy Biosimulation Platform Historic Market Size by Type (2021-2026)
- 3.2 Global Personalized Therapy Biosimulation Platform Forecasted Market Size by Type (2027-2032)
4 Personalized Therapy Biosimulation Platform Breakdown Data by Application
- 4.1 Global Personalized Therapy Biosimulation Platform Historic Market Size by Application (2021-2026)
- 4.2 Global Personalized Therapy Biosimulation Platform Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Personalized Therapy Biosimulation Platform Market Perspective (2021-2032)
- 5.2 Global Personalized Therapy Biosimulation Platform Growth Trends by Region
- 5.2.1 Global Personalized Therapy Biosimulation Platform Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Personalized Therapy Biosimulation Platform Historic Market Size by Region (2021-2026)
- 5.2.3 Personalized Therapy Biosimulation Platform Forecasted Market Size by Region (2027-2032)
- 5.3 Personalized Therapy Biosimulation Platform Market Dynamics
- 5.3.1 Personalized Therapy Biosimulation Platform Industry Trends
- 5.3.2 Personalized Therapy Biosimulation Platform Market Drivers
- 5.3.3 Personalized Therapy Biosimulation Platform Market Challenges
- 5.3.4 Personalized Therapy Biosimulation Platform Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Personalized Therapy Biosimulation Platform Players by Revenue
- 6.1.1 Global Top Personalized Therapy Biosimulation Platform Players by Revenue (2021-2026)
- 6.1.2 Global Personalized Therapy Biosimulation Platform Revenue Market Share by Players (2021-2026)
- 6.2 Global Personalized Therapy Biosimulation Platform Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Personalized Therapy Biosimulation Platform Head Office and Area Served
- 6.4 Global Personalized Therapy Biosimulation Platform Players, Product Type & Application
- 6.5 Global Personalized Therapy Biosimulation Platform Manufacturers Established Date
- 6.6 Global Personalized Therapy Biosimulation Platform Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Personalized Therapy Biosimulation Platform Market Size (2021-2032)
- 7.2 North America Personalized Therapy Biosimulation Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Personalized Therapy Biosimulation Platform Market Size by Country (2021-2026)
- 7.4 North America Personalized Therapy Biosimulation Platform Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Personalized Therapy Biosimulation Platform Market Size (2021-2032)
- 8.2 Europe Personalized Therapy Biosimulation Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Personalized Therapy Biosimulation Platform Market Size by Country (2021-2026)
- 8.4 Europe Personalized Therapy Biosimulation Platform Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Personalized Therapy Biosimulation Platform Market Size (2021-2032)
- 9.2 Asia-Pacific Personalized Therapy Biosimulation Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Personalized Therapy Biosimulation Platform Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Personalized Therapy Biosimulation Platform Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Personalized Therapy Biosimulation Platform Market Size (2021-2032)
- 10.2 South America Personalized Therapy Biosimulation Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Personalized Therapy Biosimulation Platform Market Size by Country (2021-2026)
- 10.4 South America Personalized Therapy Biosimulation Platform Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Personalized Therapy Biosimulation Platform Market Size (2021-2032)
- 11.2 Middle East & Africa Personalized Therapy Biosimulation Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Personalized Therapy Biosimulation Platform Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Personalized Therapy Biosimulation Platform Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Schrodinger
- 12.1.1 Schrodinger Company Information
- 12.1.2 Schrodinger Business Overview
- 12.1.3 Schrodinger Revenue in Personalized Therapy Biosimulation Platform Business (2021-2026)
- 12.1.4 Schrodinger Personalized Therapy Biosimulation Platform Product Portfolio
- 12.1.5 Schrodinger Recent Developments
- 12.2 In Silico Biosciences
- 12.2.1 In Silico Biosciences Company Information
- 12.2.2 In Silico Biosciences Business Overview
- 12.2.3 In Silico Biosciences Revenue in Personalized Therapy Biosimulation Platform Business (2021-2026)
- 12.2.4 In Silico Biosciences Personalized Therapy Biosimulation Platform Product Portfolio
- 12.2.5 In Silico Biosciences Recent Developments
- 12.3 Genedata
- 12.3.1 Genedata Company Information
- 12.3.2 Genedata Business Overview
- 12.3.3 Genedata Revenue in Personalized Therapy Biosimulation Platform Business (2021-2026)
- 12.3.4 Genedata Personalized Therapy Biosimulation Platform Product Portfolio
- 12.3.5 Genedata Recent Developments
- 12.4 Physiomics
- 12.4.1 Physiomics Company Information
- 12.4.2 Physiomics Business Overview
- 12.4.3 Physiomics Revenue in Personalized Therapy Biosimulation Platform Business (2021-2026)
- 12.4.4 Physiomics Personalized Therapy Biosimulation Platform Product Portfolio
- 12.4.5 Physiomics Recent Developments
- 12.5 Insilico Biotechology
- 12.5.1 Insilico Biotechology Company Information
- 12.5.2 Insilico Biotechology Business Overview
- 12.5.3 Insilico Biotechology Revenue in Personalized Therapy Biosimulation Platform Business (2021-2026)
- 12.5.4 Insilico Biotechology Personalized Therapy Biosimulation Platform Product Portfolio
- 12.5.5 Insilico Biotechology Recent Developments
- 12.6 Chemical Computing Group ULC(CCG)
- 12.6.1 Chemical Computing Group ULC(CCG) Company Information
- 12.6.2 Chemical Computing Group ULC(CCG) Business Overview
- 12.6.3 Chemical Computing Group ULC(CCG) Revenue in Personalized Therapy Biosimulation Platform Business (2021-2026)
- 12.6.4 Chemical Computing Group ULC(CCG) Personalized Therapy Biosimulation Platform Product Portfolio
- 12.6.5 Chemical Computing Group ULC(CCG) Recent Developments
- 12.7 Evidera
- 12.7.1 Evidera Company Information
- 12.7.2 Evidera Business Overview
- 12.7.3 Evidera Revenue in Personalized Therapy Biosimulation Platform Business (2021-2026)
- 12.7.4 Evidera Personalized Therapy Biosimulation Platform Product Portfolio
- 12.7.5 Evidera Recent Developments
- 12.8 AnyLogic
- 12.8.1 AnyLogic Company Information
- 12.8.2 AnyLogic Business Overview
- 12.8.3 AnyLogic Revenue in Personalized Therapy Biosimulation Platform Business (2021-2026)
- 12.8.4 AnyLogic Personalized Therapy Biosimulation Platform Product Portfolio
- 12.8.5 AnyLogic Recent Developments
- 12.9 Shanghai Lide
- 12.9.1 Shanghai Lide Company Information
- 12.9.2 Shanghai Lide Business Overview
- 12.9.3 Shanghai Lide Revenue in Personalized Therapy Biosimulation Platform Business (2021-2026)
- 12.9.4 Shanghai Lide Personalized Therapy Biosimulation Platform Product Portfolio
- 12.9.5 Shanghai Lide Recent Developments
- 12.10 Cellworks Group
- 12.10.1 Cellworks Group Company Information
- 12.10.2 Cellworks Group Business Overview
- 12.10.3 Cellworks Group Revenue in Personalized Therapy Biosimulation Platform Business (2021-2026)
- 12.10.4 Cellworks Group Personalized Therapy Biosimulation Platform Product Portfolio
- 12.10.5 Cellworks Group Recent Developments
- 12.11 Certara
- 12.11.1 Certara Company Information
- 12.11.2 Certara Business Overview
- 12.11.3 Certara Revenue in Personalized Therapy Biosimulation Platform Business (2021-2026)
- 12.11.4 Certara Personalized Therapy Biosimulation Platform Product Portfolio
- 12.11.5 Certara Recent Developments
- 12.12 Simulation Plus
- 12.12.1 Simulation Plus Company Information
- 12.12.2 Simulation Plus Business Overview
- 12.12.3 Simulation Plus Revenue in Personalized Therapy Biosimulation Platform Business (2021-2026)
- 12.12.4 Simulation Plus Personalized Therapy Biosimulation Platform Product Portfolio
- 12.12.5 Simulation Plus Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst